Wolfgang Fendler, MD, discusses the utility and pending FDA approval of 68Ga-PSMA-11 PET in prostate cancer.
Wolfgang Fendler, MD
Advertisement
Articles by Wolfgang Fendler, MD
Wolfgang Fendler, MD, discusses the rationale for creating the 68Ga-PSMA-11 PET in prostate cancer.
Wolfgang Fendler, MD, discusses the impact of 68Ga-PSMA-11 PET imaging on the clinical management of patients with prostate cancer.
Wolfgang Fendler, MD, discusses the utility of 68Ga-PSMA-11 PET in prostate cancer.
Wolfgang Fendler, MD, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, discusses the clinical need for 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer.
Advertisement
Latest Updated Articles
Dr. Fendler on Clinical Need for 68GA-PSMA-11 PET in Prostate CancerFebruary 20th 2020
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
4
Extended Pelvic Lymph Node Dissection Improves MFS in High-Grade Prostate Cancer
5